Apheris launched the ADMET Network, a federated initiative allowing pharmaceutical companies to collaboratively train AI models for ADMET predictions without sharing proprietary data. This network aims to improve drug discovery by enhancing model accuracy and generalizability across diverse chemical spaces, benefiting content creators in pharma by accelerating timelines and reducing costs through better ADMET predictions.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



